A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA(A)-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

por Goeldner, Celia, Kishnani, Priya S., Skotko, Brian G., Casero, Julian Lirio, Hipp, Joerg F., Derks, Michael, Hernandez, Maria-Clemencia, Khwaja, Omar, Lennon-Chrimes, Sian, Noeldeke, Jana, Pellicer, Sabine, Squassante, Lisa, Visootsak, Jeannie, Wandel, Christoph, Fontoura, Paulo, d’Ardhuy, Xavier Liogier
Publicado 2022

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectru...

por Bennett, Jeffrey L., Fujihara, Kazuo, Kim, Ho Jin, Marignier, Romain, O'Connor, Kevin C., Sergott, Robert C., Traboulsee, Anthony, Wiendl, Heinz, Wuerfel, Jens, Zamvil, Scott S., Anania, Veronica G., Buffels, Regine, Künzel, Thomas, Lekkerkerker, Annemarie N., Lennon-Chrimes, Siân, Pittock, Sean J.
Publicado 2023

Basmisanil, a highly selective GABA(A)-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man

por Hipp, Joerg F., Knoflach, Frederic, Comley, Robert, Ballard, Theresa M., Honer, Michael, Trube, Gerhard, Gasser, Rodolfo, Prinssen, Eric, Wallace, Tanya L., Rothfuss, Andreas, Knust, Henner, Lennon-Chrimes, Sian, Derks, Michael, Bentley, Darren, Squassante, Lisa, Nave, Stephane, Nöldeke, Jana, Wandel, Christoph, Thomas, Andrew W., Hernandez, Maria-Clemencia
Publicado 2021